Neoadjuvant Intralesional Daromun in Resectable Melanoma: Interpreting the PIVOTAL Trial

What a randomized trial of local treatment tells us about recurrence, distant disease control, and the evolving neoadjuvant landscape.

Melanoma
Neoadjuvant Therapy
Intralesional Therapy
PIVOTAL
Clinical Trials
A research perspective on neoadjuvant intralesional daromun in the randomized PIVOTAL trial: population, recurrence-free and distant metastasis-free survival, the interpretation of perioperative endpoints, and clinical placement.
Authors

David M. Miller

Elizabeth I. Buchbinder

Isaac Brownell

Karam Khaddour

Nikhil I. Khushalani

Justine V. Cohen

Vishal A. Patel

Michael K. Wong

Published

Oct 9, 2026

Perspectives on the Science · Journal of Cutaneous Oncology Published October 9, 2026 · Volume 4, Issue 2

Miller DM, Buchbinder EI, Brownell I, Khaddour K, Khushalani NI, Cohen JV, Patel VA, Wong MK. Neoadjuvant Intralesional Daromun in Resectable Melanoma: Interpreting the PIVOTAL Trial. Journal of Cutaneous Oncology. 2026;4(2). doi:10.59449/joco.2026.09.25.

PIVOTAL tested whether a brief course of locally administered immunocytokine therapy before surgery could improve outcomes in patients with resectable stage III melanoma. Its randomized results are compelling, but they also raise questions about what the endpoints measure, how much benefit extends beyond injected lesions, and where daromun fits alongside modern neoadjuvant immunotherapy.

Why this Perspective matters

PIVOTAL randomized 256 patients with resectable stage III melanoma and injectable disease to as many as four weekly doses of intralesional daromun followed by surgery, or to upfront surgery. Importantly, 222 patients (87%) had recurrent disease, a population of particular relevance as more patients relapse after previous surgery and systemic treatment.

Yet recurrent disease is not synonymous with anti–PD-1-refractory disease: only 47 participants had previously received an immune checkpoint inhibitor. The trial therefore provides randomized evidence in a largely recurrent population, but less direct evidence in the treatment-resistant population now frequently encountered in clinical practice.

The randomized results

Recurrence-free survival
HR 0.55
23.8 vs 6.5 months median RFS
Daromun followed by surgery vs upfront surgery
Distant metastasis-free survival
HR 0.53
38.7 vs 14.0 months median DMFS
Daromun followed by surgery vs upfront surgery
Event-free survival · post hoc
HR 0.71
16.1 vs 6.1 months median EFS
Retrospective analysis of perioperative events
Median outcomes · months
Outcome
Daromun + surgery
Surgery alone
RFS
23.8
6.5
DMFS
38.7
14.0
EFS (post hoc)
16.1
6.1
Bars use a common 0–40-month scale. Medians are not treatment-effect estimates; hazard ratios above summarize the randomized time-to-event comparisons. EFS was evaluated post hoc. Source: updated PIVOTAL analysis in Journal of Clinical Oncology (2026).
Central perspective
The strongest evidence is that daromun followed by surgery improves disease-control outcomes compared with upfront surgery. The harder question is how that strategy compares with contemporary systemic neoadjuvant treatment, particularly after prior checkpoint blockade.

What does the endpoint really measure?

RFS began at randomization, not surgery. The trial’s later EFS analysis used the same time origin but counted additional preoperative failures, including events that could prevent definitive surgery. The favorable post hoc EFS result is consistent with the primary analysis, but its retrospective definition matters when comparing PIVOTAL with newer neoadjuvant trials.

What does distant disease control tell us?

Daromun is injected directly into accessible tumor deposits. The favorable distant metastasis-free survival result, obtained in a randomized comparison, therefore carries more weight for disease control beyond injected lesions than local tumor regression alone. It does not, however, identify the biological mechanism responsible.

Postoperative therapy complicates interpretation: more patients in the surgery-alone group received subsequent adjuvant treatment (54 versus 41; checkpoint inhibitors in 38 versus 28). Those treatments were not randomized, so their contribution cannot be isolated from these data.

How should we think about treatment burden?

Grade 3 or higher adverse events occurred in 33.6% of patients assigned to daromun and 11.3% in the control arm; grade 3 treatment-related events occurred in 28.7% and 7.3%, respectively. Injection-site reactions were an important component of the daromun safety profile. No treatment-related deaths were reported.

The relevant clinical comparison is not simply local treatment versus systemic treatment. It is the total perioperative strategy: disease control, immune toxicity, surgical morbidity, treatment duration, postoperative therapy, and patient experience.

Where might daromun fit next?

The most informative next questions concern resectable recurrence following anti–PD-1 or BRAF/MEK therapy, rational sequencing with systemic immunotherapy, and whether response to intralesional treatment can help tailor surgery or postoperative treatment. The ongoing NeoDREAM trial should add evidence in a more contemporary perioperative setting.

The RP1 plus nivolumab experience in unresectable, post–PD-1 melanoma provides useful context, but it is not a direct comparator: the drug, treatment combination, population, and design differ from PIVOTAL.

What The Readout discussion added

September 25, 2026 · Society of Cutaneous Oncology
62% rated the evidence very compelling

After the discussion, 13 of 21 respondents rated the findings very compelling and eight rated them moderately compelling. The pre-session and post-session surveys were aggregate and unpaired.

The session highlighted the value of examining endpoint definitions, recurrence history, and the distinction between local and distant disease control before trying to place daromun within current melanoma treatment pathways.

Read the published article

The Miller Lab page highlights selected conclusions and interpretive questions from the published Perspective rather than reproducing the full manuscript, bibliography, author disclosures, or methodology. For the complete scientific discussion and references, please consult the published article in the Journal of Cutaneous Oncology.

The interpretation and opinions presented in the published Perspective are those of its authors, not an official position of their institutions or the Society of Cutaneous Oncology. The publication date above is the original October 9, 2026 article date; this Miller Lab summary is a companion page, not a new journal publication.